

West Nile Virus Infections - Pipeline Review, H1 2018

<https://marketpublishers.com/r/WF7B6BADFF1EN.html>

Date: March 2018

Pages: 67

Price: US\$ 2,000.00 (Single User License)

ID: WF7B6BADFF1EN

Abstracts

West Nile Virus Infections - Pipeline Review, H1 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide West Nile Virus Infections - Pipeline Review, H1 2018, provides an overview of the West Nile Virus Infections (Infectious Disease) pipeline landscape.

West Nile infection is caused by a virus transmitted by mosquitoes. The West Nile virus is a type of virus known as a Flavivirus. Symptoms include a fever, headache, body aches, skin rash, and swollen lymph glands. Risk factors for developing a more severe form of West Nile virus include conditions that weaken the immune system, such as HIV, organ transplants, and recent chemotherapy, age and pregnancy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide West Nile Virus Infections - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for West Nile Virus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The West Nile Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for West Nile Virus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase

I, Preclinical and Discovery stages are 4, 7 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 3 and 2 molecules, respectively.

West Nile Virus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of West Nile Virus Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for West Nile Virus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in West Nile Virus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates West Nile Virus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for West Nile Virus Infections (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for West Nile Virus Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding West Nile Virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- West Nile Virus Infections - Overview
- West Nile Virus Infections - Therapeutics Development Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- West Nile Virus Infections - Therapeutics Assessment
 - Assessment by Target
 - Assessment by Mechanism of Action
 - Assessment by Route of Administration
 - Assessment by Molecule Type
- West Nile Virus Infections - Companies Involved in Therapeutics Development
 - CEL-SCI Corp
 - Ennaid Therapeutics LLC
 - Hawaii Biotech Inc
 - Hemispherx Biopharma Inc
 - Kineta Inc
 - Ology Bioservices Inc
 - Plex Pharmaceuticals Inc
- West Nile Virus Infections - Drug Profiles
 - AGS-v - Drug Profile
 - Product Description
 - Mechanism Of Action
 - R&D Progress
 - Alferon LDO - Drug Profile
 - Product Description
 - Mechanism Of Action
 - R&D Progress
 - BG-323 - Drug Profile
 - Product Description
 - Mechanism Of Action
 - R&D Progress
 - Bispecific Monoclonal Antibody for West Nile Virus Infections - Drug Profile
 - Product Description

Mechanism Of Action

R&D Progress

CEL-1000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETX-112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HBV-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HydroVax-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interferon alfa-n3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KIN-1148 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KIN-1400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rintatolimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit NS2B-NS3 Protease for Dengue, West Nile Virus and Zika

Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tatbeclin-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

West Nile virus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

West Nile virus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

West Nile Virus Infections - Dormant Projects

West Nile Virus Infections - Product Development Milestones

Featured News & Press Releases

Feb 21, 2017: hVIVO notes the initiation of a Phase I clinical trial with AGS-v, a mosquito-borne disease vaccine candidate

Jul 06, 2015: NIH-funded vaccine for West Nile Virus enters human clinical trials

May 05, 2014: Alferon N Effective Against MERS Virus In-Vitro

Sep 12, 2013: Hemispherx Announces Initial Test Results in Biosecurity/Biodefense Arena

Sep 06, 2011: Hemispherx Enters Into Strategic Alliance With Armada Health Care For Alferon N Injection

Apr 20, 2010: Kineta Scientist to Present Novel Antiviral Research Findings at International Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development for West Nile Virus Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

West Nile Virus Infections - Pipeline by CEL-SCI Corp, H1 2018

West Nile Virus Infections - Pipeline by Ennaid Therapeutics LLC, H1 2018

West Nile Virus Infections - Pipeline by Hawaii Biotech Inc, H1 2018

West Nile Virus Infections - Pipeline by Hemispherx Biopharma Inc, H1 2018

West Nile Virus Infections - Pipeline by Kineta Inc, H1 2018

West Nile Virus Infections - Pipeline by Ology Bioservices Inc, H1 2018

West Nile Virus Infections - Pipeline by Plex Pharmaceuticals Inc, H1 2018

West Nile Virus Infections - Dormant Projects, H1 2018

West Nile Virus Infections - Dormant Projects, H1 2018 (Contd..1), H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development for West Nile Virus Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

CEL-SCI Corp

Ennaid Therapeutics LLC

Hawaii Biotech Inc

Hemispherx Biopharma Inc

Kineta Inc

Ology Bioservices Inc

Plex Pharmaceuticals Inc

I would like to order

Product name: West Nile Virus Infections - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/WF7B6BADFF1EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/WF7B6BADFF1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970